Zymergen Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zymergen Inc. Zymergen Inc. was a biotechnology company that developed bio-based materials and microbes using machine learning, genomics, automation, and data science; its core products included Hyaline, a bio-manufactured transparent polyimide film for flexible electronics such as foldable smartphones and tablets, along with engineered microbes and molecules for applications in chemicals, pharmaceuticals, consumer goods, agriculture, packaging, and healthcare. Founded in 2013 and headquartered in Emeryville, California, the company operated primarily in the United States and targeted electronics, manufacturing, and industrial sectors with its platform for designing genetically modified organisms to produce sustainable alternatives to petroleum-based products. In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal completed in October 2022, integrating its automation, software, and biological engineering technologies into Ginkgo's cell programming platform while pursuing strategic alternatives for Zymergen's advanced materials and drug discovery programs; the company underwent significant cost restructuring, including multiple layoffs reducing headcount by half, discontinuation of Hyaline production in November 2021, and a pivot to drug development prior to the acquisition. Zymergen filed for Chapter 11 bankruptcy on October 3, 2023, in the U.S. Bankruptcy Court for the District of Delaware, followed by court confirmation of its liquidation plan on February 5, 2024, after selling remaining assets amid operational challenges and SEC charges in September 2024 for misleading IPO disclosures related to market potential and revenue prospects, resulting in a $30 million civil penalty. As a former subsidiary of Ginkgo Bioworks Holdings Inc. Ginkgo Bioworks Holdings, Inc., Zymergen ceased independent operations following liquidation.
SEC Charges Zymergen Inc. With Misleading IPO Investors About Company's Market Potential and Sales Prospects
Ginkgo Bioworks Completes Acquisition of Zymergen
ZYMERGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zymergen - ZY
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ
Investor Alert - The M&A Class Action Firm Announces the Investigation of Zymergen Inc. - ZY
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates IEA, ZY, FLAC
SHAREHOLDER ALERT: Weiss Law Investigates Infrastructure and Zymergen Inc.
Why Ginkgo Bioworks (DNA) Is Buying Zymergen For $300 Million
Shareholder Alert: Ademi LLP investigates whether Zymergen Inc. has obtained a Fair Price in its transaction with Ginkgo
Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million
Gingko Buys Embattled Biotech Firm Zymergen For Paltry $300 Million
ZY Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Zymergen Inc. Is Fair to Shareholders
Ginkgo to Acquire Zymergen
Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform
Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications
Good Penny Stocks to Buy Now? 3 to Watch in June
Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform
Zymergen: A Humbled Company With A Business On The Ropes
Zymergen, Inc. (ZY) CEO Jay Flatley on Q1 2022 Results - Earnings Call Transcript